White Papers

Narrow results by:

How a U.S. COVID-19 Data Registry Fuels Global Research

October 21, 2020

Posted In: COVID-19 Response, Data and Analytics, Life Sciences

In addition to driving COVID-19 understanding within the United States, a national disease registry is informing research beyond U.S. borders. Clinicians with the Singapore Ministry of Healthcare Office for Healthcare Transformation (MOHT) have used Health Catalyst Touchstone® COVID-19 data to develop a machine learning tool that helps predict the likelihood of COVID-19 mortality. With this national data set that leverages deep aggregated EHR data, the MOHT accessed the research-grade data it needed to build a machine-learning algorithm that predicts risk of death from COVID-19. The registry-informed prediction model was accurate enough to stand up to comparisons in the published literature and promises to help inform vaccine research and, ultimately, allocation of vaccines within populations.

Extended Real-World Data: The Life Science Industry’s Number One Asset

March 27, 2019

Posted In: Data and Analytics, Life Sciences

The life science industry has historically relied on sanitized clinical trials and commoditized data sources (largely claims) to inform its drug development process—an under-substantiated approach that didn’t reflect how a new drug would affect broader patient populations. In an effort to gain more accurate insight into the patient experience and bring drugs to market more efficiently and safely, the industry is now expanding into extended real-world data (RWD).To access the needed breadth and depth of patient-centric data, life science companies must partner with a healthcare transformation company that has three key qualities:1. A broad and deep data asset.2. Extensive provider partnerships.3. An outcomes-improvement engine to support the next generation of drug development.